The macrocyclic lactone bryostatin-1 was found to exert in vitro antineoplastic activity against several leukemic cell lines, including human K562 erythroleukemia, HL60 promyelocytic leukemia, REH and MOLT-4 lymphoblastic leukemias, CCRFCEM lymphoma, KG-1 myeloid leukemia, and murine P388 lymphocytic leukemia. No statistically significant difference in sensitivity to bryostatin-1 was found between adriamycin-resistant P388 and K526 subclones and their sensitive counterparts. Freshly explanted clonogenic leukemic cells showed a variable sensitivity to bryostatin-1 in 10/12 tested samples. The IC50 of clonogenic leukemic cells was 4 × 10–3 M bryostatin-1, and that of normal marrow CFU-GM was 10–5 M. Leukemic cells exposed to bryostatin-1 showed a variable degree of monocytic differentiation as evaluated by ANAE staining and morphology. Bryostatin-1 is also able to inhibit the growth of CFU-GM from myelodysplastic marrow and to shorten the duration of dysplastic hematopoiesis in liquid culture. In conclusion, these data suggest that bryostatin-1 is a potent antileukemic agent in vitro that may be potentially useful for clinical studies.
Get full access to this article
View all access options for this article.
References
1.
BerkowR.L., KraftA.S.: Bryostatin a non-phorbol macrocyclic lactone activates intact human polymorphounuclear leukocytes and binds to phorbol ester receptors. Biochem. Biophys. Res. Commun., 131: 1109–1116, 1985.
2.
BlumbergP.M.: Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture. Cancer Res., 48: 1–8, 1988.
3.
BoyumA.: Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest., 21: suppl. 97, 77–81, 1968.
4.
BuickR.N., TillJ.E., McCullochE.A.: Colony assay for proliferating blast cells circulating in myeloblastic leukemia. Lancet, 1: 862–865, 1977.
5.
Dell'AquilaM.L., NguyenH.T., HeralC.L., PettitG.R., BlumbergP.M.: Inhibition by bryostatin-1 of the phorbol ester-induced blockage of differentiation in hexamethylene bisacetamide-treated Friend erythroleukemia cells. Cancer Res., 47: 6006–6009, 1987.
GebbiaV., CitarrellaP., Di MarcoP., Tambone ReyesM., RausaL., MayW.S.: Bryostatin-1 stimulates murine hematopoietic stem cells in vitro. XXII Congress of the International Society of Hematology, 153, 1988.
8.
GebbiaV., MunshiN., Di MarcoP., CitarrellaP., MayW.S.: The antineoplastic agent bryostatin-1 induces the proliferation of human peripheral T lymphocytes in vitro. XXII Congress of the International Society of Hematology, p. 123, 1988.
9.
GebbiaV., Di MarcoP., MiceliS., Tambone ReyesM., TeresiM., BonaccorsoR., CitarrellaP., RausaL.: The in vitro effect of the antineoplastic agent bryostatin-4 on human hematopoietic progenitor cells. Haematologica, 73: 387–391, 1988.
10.
GebbiaV., MiserendinoV., MiceliS., ColucciA., Tambone ReyesM., RausaL., Di MarcoP., CitarrellaP.: Analysis of human dysplastic haematopoiesis in long-term bone marrow culture. Blut, 59: 442–446, 1989.
11.
GebbiaV., GebbiaN., RausaL., SharkisS.J., MayW.S.: In vivo stimulation of murine hematopoiesis by the antineoplastic agent bryostatin-1. Pharmacol. Res., 22, suppl.1: 103–104, 1990.
12.
GralnickH.R., GaltonD.A.G., CatovskyD., SultanC., BennettJ.M.: Classification of acute leukemia. Ann. Intern. Med., 87: 740–751, 1977.
13.
GreenbergerJ.S.: Recent modification of technique in human long-term bone marrow cultures. In: Long-term bone marrow culture, WrightD.G., GreenbergerJ.S. (Eds.), pp. 119–132, A.R. Liss, New York, 1984.
14.
KraftA.S., SmithJ.B., BerkowR.L.: Bryostatin, an activator of calcium phospholipid-dependent protein kinase blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL60. Proc. Natl. Acad. Sci. USA, 83: 1334–1338, 1986.
15.
LeonardJ.P., MayW.S., IhleJ.N., PettitG.R., SharkisS.J.: Regulation of hematopoiesis. IV: The role of interleukin-3 and bryostatin-1 in the growth of erythropoietic progenitors from normal and anemic W/Wv mice. Blood, 72: 1492–1496, 1988.
16.
MayW.S., SharkisS.J., EsaA.H., GebbiaV., KraftA.S., PettitG.R., SensenbrennerL.L.: Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc. Natl. Acad. Sci. USA, 84: 8483–8487, 1987.
17.
PettitG.R., HeraldC.L., DoubekD.L., HeraldD.L.: Isolation and structure of bryostatin-1. J. Am. Chem. Soc., 104: 6846–6848, 1982.
18.
PettitG.R., KamanoY., HeraldC.L., TozawaM.: Structure of bryostatin 4. An important antineoplastic component of geographically diverse Bugula Neritina. J. Am. Chem. Soc., 106: 6268–6271, 1984.
19.
PettitG.R., KamanoY., HeraldC.L., TozawaM.: Isolation and structure of bryostatins 5-7. Can J. Chem., 63: 1204–1208, 1985.
20.
PikeB.L., RobinsonW.A.: Human bone marrow colony growth in agar gel. J. Cell. Physiol., 76: 77–83, 1970.
21.
PincusS.M., FieldsA.P., MayW.S.: Rapid phosphorylation of a major 100 KD nuclear envelope polypeptide in IL-3-dependent cells induced by both IL-3 and bryostatin. Blood, 72, suppl.1: 131, 1988.
22.
RamuA., CohenL., GlaubigerD.: Oxygen radical detoxification enzymes in doxorubicin-sensitive and -resistant P388 murine leukemia cells. Cancer Res., 44: 1976–1980, 1984.
23.
StevensD.A., CelanoP., MayW.S.: Effect of bryostatin and phorbol esters on protein kinase C mRNA levels in HL60 cells. Blood, 72, suppl.1: 184, 1988.
24.
StoneR.M., SaribanE., PettitG.R., KufeD.W.: Bryostatin-1 activates protein kinase C and induces monocytic differentiation of HL60 cells. Blood, 72: 208–213, 1988.
25.
TapieroH., MunckJ.N., FourcadeA., LampidisT.J.: Cross-resistance to rhodamine 123 in adriamycin- and daunomycin-resistant Friend leukemia cell variants. Cancer Res., 44: 5544–5549, 1984.
26.
TrennG., PettitG.R., TakayamaH., Hu-liJ., SitkowskyM.V.: Immunomodulating properties of a novel series of protein kinase C activators: the bryostatins. J. Immunol., 140: 433–439, 1988.
